Management of Small Bilateral Echogenic Testicular Lesions in an 83-Year-Old Man
In this 83-year-old man with bilateral 4 mm echogenic testicular lesions lacking vascularity or shadowing, obtain serum tumor markers (AFP, hCG, LDH) immediately and perform repeat scrotal ultrasound in 6-8 weeks to assess for interval change. 1
Initial Workup Algorithm
The 2019 AUA guideline provides clear direction for indeterminate testicular findings:
- Serum tumor markers are mandatory before any intervention, even when lesions appear benign. Draw AFP, hCG, and LDH now 1
- Patients with normal tumor markers and indeterminate ultrasound findings should undergo repeat imaging in 6-8 weeks 1
This approach is particularly appropriate here because:
- The lesions are echogenic (not the typical hypoechoic pattern of malignancy)
- They lack vascularity (malignant masses typically show vascular flow) 1
- They are very small (4 mm)
- They lack acoustic shadowing (which would suggest calcification)
Risk Stratification Based on Lesion Characteristics
Key features that lower malignancy risk in this case:
- Size <5 mm: Research shows 50-80% of non-palpable masses <2 cm are benign 1. Your patient's 4 mm lesions fall well below this threshold
- Bilateral presentation: Synchronous bilateral malignancy is rare (2-3% lifetime risk) 2
- Echogenic appearance: Malignant testicular tumors are characteristically hypoechoic with vascular flow 1
- Absence of vascularity: Studies demonstrate that avascular lesions have substantially lower malignancy rates 3
- Advanced age: At 83 years, this patient is well beyond the typical age range for germ cell tumors (20-40 years) 4
Surveillance Protocol
If tumor markers are normal and repeat ultrasound at 6-8 weeks shows stability:
- Continue surveillance with ultrasound every 3-6 months initially 5, 6, 7
- Monitor for any of these concerning changes:
- Lesion growth (>2 mm increase)
- Development of vascularity on Doppler
- Change from echogenic to hypoechoic pattern
- Rising tumor markers
- New symptoms or palpable abnormality
Recent evidence strongly supports this conservative approach: A 2023 study of 307 men with small testicular masses ≤20 mm found that surveillance was safe, with only 4.3% malignancy rate in the surveillance cohort 5. Another 2018 study of 120 subcentimeter masses showed mean lesion growth of -0.01 mm/year, with no patients developing advanced disease 8.
When to Escalate Management
Proceed to surgical intervention if:
- Tumor markers become elevated
- Lesion grows on serial imaging
- Vascularity develops on Doppler ultrasound
- Echogenicity pattern changes to hypoechoic
- Patient develops symptoms or palpable mass
Surgical options in order of preference for small lesions:
- Testis-sparing surgery with frozen section (preferred for lesions <2 cm in bilateral disease) 1
- Radical inguinal orchiectomy (if frozen section shows malignancy or patient preference)
Critical Pitfalls to Avoid
Do NOT:
- Perform scrotal biopsy or scrotal incision (violates lymphatic drainage) 2
- Use MRI as initial evaluation 1, 9
- Proceed directly to orchiectomy without tumor markers and surveillance period
- Ignore the patient's age and comorbidities when weighing intervention risks
Common mistake: Treating all solid testicular lesions as malignant. The AUA guideline states this principle applies to solid masses, but your patient has small echogenic foci that are nonspecific and likely benign based on imaging characteristics 1.
Age-Specific Considerations
At 83 years old, this patient's life expectancy and competing mortality risks must factor into decision-making. Even if these lesions were malignant (highly unlikely given characteristics):
- Stage I seminoma has nearly 100% cure rate 9
- Surveillance would detect progression early enough for curative treatment
- Surgical risks and impact on quality of life may outweigh benefits of immediate intervention
The evidence supports watchful waiting with structured surveillance as the most appropriate strategy, prioritizing quality of life while maintaining oncologic safety.